FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557703775> ?p ?o ?g. }

• W2557703775 endingPage "e117" @default.
• W2557703775 startingPage "e114" @default.
• W2557703775 abstract "To the Editors: Expert guidelines now recommend immediate antiretroviral therapy (ART) for all HIV-infected persons regardless of CD4 cell count, to reduce the risk of disease progression and prevent HIV transmission.1,2 There is also increasing evidence that very early ART benefits the individual infected with HIV by leading to more rapid and robust immunologic recovery, lower inflammation, and reduced viral reservoir size compared with a later start.3–12 However, in low-income and middle-income countries, universal immediate ART is rarely available. To assist clinicians in regions where universal ART is not available in prioritizing provision of immediate ART to patients who benefit most, Braun et al recently developed the Acute Retroviral Syndrome (ARS) Severity Score (ARSSS). Following the hypothesis that severity of primary HIV infection correlates with disease progression,13–17 the score includes mostly clinical variables that reflect the intensity of the clinical presentation of primary HIV infection.18 The score was evaluated retrospectively among 290 individuals of the Zurich primary HIV infection study and correlated well with validated surrogate markers associated with HIV-1 disease progression, that is, baseline CD4+ cell count, baseline viral load, and set-point viral load.18 External validation of the ARSSS is still missing, however. Furthermore, it remains unclear if the score has predictive validity also in individuals at the earliest stage of HIV infection, as only 3 of these 290 individuals fulfilled the earliest criteria of acute HIV infection (AHI; ie, Fiebig I or II).18,19 In this retrospective analysis of a prospective observational cohort study, we evaluated the performance of the ARSSS18 in patients diagnosed with AHI between 2007 and 2014 by the San Diego Primary HIV Infection Consortium.20 A total of 90 persons were identified with AHI and provided questionnaire responses on signs and symptoms of ARS at the time of AHI diagnosis, although only the subset of 48 individuals who provided information on whether they had sought medical attention for signs or symptoms of ARS (ie, a substantial 3-point component of the ARSSS) were included in this analysis (the question was not included in the questionnaire used between 2010 and 2012). All individuals were diagnosed with AHI with the “Early Test” that included routine individual donation (ID), HIV nucleic acid amplification testing (ID-NAT) to all rapid antibody-negative participants.21–26 AHI was defined as having a negative or indeterminate HIV antibody test result with a positive ID-NAT, corresponding to Fiebig stages I–II, and a mean estimated duration of infection of 10 days.19 At each participant's first visit after documentation of AHI diagnosis (median 4 days, interquartile range , 3–6 days after AHI testing), blood samples were collected for CD4 and viral load testing. Detailed information related to occurrence, duration, and start and stop dates for signs and symptoms associated with AHI were also collected.27,28 Participants were asked if they had sought medical attention for any of these signs or any symptoms. In persons who reported symptoms that were ongoing, the date on which symptoms resolved as well as additional signs or symptoms occurring within 4 weeks after the AHI test were collected during follow-up.20 The viral set point was defined as the first HIV-RNA measurement ≥90 days after the estimated date of infection in treatment-naive patients.18 We evaluated 2 versions of the ARSSS, the complete 6 variable27 ARSSS assessment (ARSSS-full) in a subset of 19 participants and a shorted version (ARSSS-short) consisting of 4 variables in all 48 participants (Table 1).TABLE 1.: Short Version and Full Version of the ARSS Score, Demographics, and Clinical Characteristics of the Study Population and Comparison of Subcohorts With Short ARSSS >2 and ≤2For this evaluation, one of the originally proposed variables, “inpatient treatment” (ie, 3 points in ARSSS), was replaced by “seeking medical attention because of signs and symptoms of ARS,” as inpatient treatment was not assessed in our cohort undergoing community-based testing. The other 3 variables of the ARSSS-short, namely presence of severe neurologic symptoms (eg, encephalitis, meningitis; 3 points), age ≥50 years (1 point), and fever (self-reported or documented ≥38°C; 1 point) remained unchanged and were assessed at the first visit after AHI diagnosis in all 48 individuals. The ARSSS-full consisting of all 6 variables was assessed in the subset of 19/48 (40%) of participants who had safety laboratory results available (ie, those who initiated ART immediately after AHI diagnosis; laboratory results were always obtained before ART start). For statistical analysis, SPSS version 23 (SPSS, Inc., Chicago, IL) was used. Correlation between ARSSS-short and ARSSS-full and viral loads, CD4/CD8 cell ratios, set-point viral loads and number, and duration of symptoms of ARS were calculated using Spearman correlation analysis due to the non-normal distributions of ARSSS and laboratory values. The University of California San Diego's Human Research Protections Program approved the study protocol, consent process, and all study-related procedures. The study cohort composed of 48 participants with AHI. All 48 were men who have sex with men. Characteristics of the study cohort are given in Table 1. The most frequently reported symptom was fever (71%), followed by fatigue (67%), and myalgia (58%). The cohort had a median ARSSS-short of 1 (range, 0–7; 23% had a score of 0, 48% a score of 1, each 4% a score of 2 and 3, and 21% a score of 4 or above; Table 1). The ARSSS-short was significantly negatively correlated with CD4/CD8 cell ratio (Spearman ρ = −0.293; P = 0.043) and positively correlated with viral load (ρ = 0.505; P < 0.001). Significant positive correlations were also observed between the ARSSS-short and number of signs and symptoms of ARS (ρ = 0.567; P < 0.001) and the total duration of signs and symptoms of ARS (ρ = 0.398; P = 0.007). No significant correlations were observed between ARSSS-short and CD4 cell count (ρ = −0.045; P > 0.2) and set point viral load (available in those 25/48 participants who started ART ≥90 days after the Estimated Date of Infection (EDI); ρ = −0.064; n.s.). Those with ARSSS-short >2 had significantly lower CD4/CD8 cell ratios, higher viral loads, longer duration of symptoms, and a trend toward more signs and symptoms than those with scores ≤2 (results and P values calculated using Mann–Whitney U test are depicted in Table 1). In the 19 individuals with available safety laboratory results, the ARSSS-full (median 1, range 0–8) did not correlate significantly with viral load (ρ = 0.315; P = 0.19), CD4/CD8 cell ratio (ρ = 0.037; P > 0.2), or CD4 count (ρ = −0.039; P > 0.2). Although a significant correlation was observed between ARSSS-full and number of signs and symptoms (ρ = 0.543; P = 0.024), there was no significant correlation with duration of signs and symptoms (ρ = 0.300; P > 0.2). Correlations of the ARSSS-short in the subset were as follows: viral loads (ρ = 0.463; P = 0.046), CD4/CD8 ratios (ρ = −0.073; n.s.), CD4 (ρ = −0.063; n.s.), number of signs and symptoms (ρ = 0.418; n.s.), and duration of signs and symptoms (0.433; n.s.). We evaluated the ARSSS, a score to identify individuals with the most severe clinical presentations of ARS who might profit most of immediate ART, among 48 individuals with AHI with an Estimated Date of Infection (EDI) of 10 days at the time of HIV diagnosis. We found that the short version of the score, limited to age and clinical variables that can all be collected at the time of HIV diagnosis, correlated well with severity of ARS in our study cohort, with significant positive correlations between ARSSS-short and viral load, number of ARS signs and symptoms and total duration of signs and symptoms, and a negative correlation between ARSSS-short and CD4/CD8 cell ratios. After being validated in another study, the ARSSS-short may therefore be used to predict diseases severity at the time of HIV diagnosis and therefore significantly earlier than other markers of disease severity. Although immediate ART for all AHI cases is clearly preferable and reflects current recommendations,1,2 a ARSSS cutoff of >2 may be used for immediate treatment in resource-limited setting, where drug use has to be triaged and is available for only about 25% of AHI cases. The ARSSS-full (which includes the ARSSS-short variables, plus platelet count and transaminases18) could only be evaluated in the subset of participants. Interestingly, integration of laboratory variables into the score in this subset did not improve performance of the score when compared with the ARSSS-short (ie, consisting of clinical variables only). This finding may relate to the small sample size of the subset with safety laboratory results. Previous studies have shown that low platelet count29,30 and elevated transaminases31 correlate with HIV-1 disease progression in individuals with recent and chronic HIV infection. However, the prognostic potential of these 2 laboratory values specifically in the earliest stages of HIV infection (ie, Fiebig I and II) has not been evaluated. In conclusion, the ARSSS-short, which includes 4 easily assessed clinical and demographic variables, may provide a simple and reliable severity score for ARS, and may help identify individuals with the greatest risk of disease progression who would benefit the most from early ART. After validation in another study, the ARSSS-short may therefore help to prioritize treatment in regions where ART is not universally available." @default.
• W2557703775 created "2016-12-08" @default.
• W2557703775 creator A5013001358 @default.
• W2557703775 creator A5031971984 @default.
• W2557703775 creator A5060121384 @default.
• W2557703775 creator A5060727664 @default.
• W2557703775 creator A5069244385 @default.
• W2557703775 date "2017-04-01" @default.
• W2557703775 modified "2023-10-16" @default.
• W2557703775 title "Evaluation of the Predictive Potential of the Short Acute Retroviral Syndrome Severity Score for HIV-1 Disease Progression in Individuals With Acute HIV Infection" @default.
• W2557703775 cites W1850893856 @default.
• W2557703775 cites W1892512609 @default.
• W2557703775 cites W1973741816 @default.
• W2557703775 cites W1976243778 @default.
• W2557703775 cites W1983279331 @default.
• W2557703775 cites W2005006791 @default.
• W2557703775 cites W2009573893 @default.
• W2557703775 cites W2010722833 @default.
• W2557703775 cites W2011208161 @default.
• W2557703775 cites W2020512200 @default.
• W2557703775 cites W2022089361 @default.
• W2557703775 cites W2026615262 @default.
• W2557703775 cites W2059761504 @default.
• W2557703775 cites W2067914298 @default.
• W2557703775 cites W2095873112 @default.
• W2557703775 cites W2121892114 @default.
• W2557703775 cites W2123027218 @default.
• W2557703775 cites W2126141460 @default.
• W2557703775 cites W2148750104 @default.
• W2557703775 cites W2152505869 @default.
• W2557703775 cites W2169249122 @default.
• W2557703775 cites W2170419954 @default.
• W2557703775 cites W2183205588 @default.
• W2557703775 cites W2209647006 @default.
• W2557703775 cites W2238552371 @default.
• W2557703775 cites W2302748448 @default.
• W2557703775 cites W2321369061 @default.
• W2557703775 cites W2322028936 @default.
• W2557703775 cites W2345928922 @default.
• W2557703775 cites W2408540832 @default.
• W2557703775 cites W2513874557 @default.
• W2557703775 cites W4240243247 @default.
• W2557703775 doi "https://doi.org/10.1097/qai.0000000000001263" @default.
• W2557703775 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5324781" @default.
• W2557703775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28225720" @default.
• W2557703775 hasPublicationYear "2017" @default.
• W2557703775 type Work @default.
• W2557703775 sameAs 2557703775 @default.
• W2557703775 citedByCount "4" @default.
• W2557703775 countsByYear W25577037752018 @default.
• W2557703775 countsByYear W25577037752020 @default.
• W2557703775 countsByYear W25577037752021 @default.
• W2557703775 countsByYear W25577037752022 @default.
• W2557703775 crossrefType "journal-article" @default.
• W2557703775 hasAuthorship W2557703775A5013001358 @default.
• W2557703775 hasAuthorship W2557703775A5031971984 @default.
• W2557703775 hasAuthorship W2557703775A5060121384 @default.
• W2557703775 hasAuthorship W2557703775A5060727664 @default.
• W2557703775 hasAuthorship W2557703775A5069244385 @default.
• W2557703775 hasBestOaLocation W25577037752 @default.
• W2557703775 hasConcept C126322002 @default.
• W2557703775 hasConcept C159047783 @default.
• W2557703775 hasConcept C203014093 @default.
• W2557703775 hasConcept C2779134260 @default.
• W2557703775 hasConcept C30036603 @default.
• W2557703775 hasConcept C3013748606 @default.
• W2557703775 hasConcept C71924100 @default.
• W2557703775 hasConceptScore W2557703775C126322002 @default.
• W2557703775 hasConceptScore W2557703775C159047783 @default.
• W2557703775 hasConceptScore W2557703775C203014093 @default.
• W2557703775 hasConceptScore W2557703775C2779134260 @default.
• W2557703775 hasConceptScore W2557703775C30036603 @default.
• W2557703775 hasConceptScore W2557703775C3013748606 @default.
• W2557703775 hasConceptScore W2557703775C71924100 @default.
• W2557703775 hasIssue "4" @default.
• W2557703775 hasLocation W25577037751 @default.
• W2557703775 hasLocation W25577037752 @default.
• W2557703775 hasLocation W25577037753 @default.
• W2557703775 hasLocation W25577037754 @default.
• W2557703775 hasLocation W25577037755 @default.
• W2557703775 hasLocation W25577037756 @default.
• W2557703775 hasLocation W25577037757 @default.
• W2557703775 hasOpenAccess W2557703775 @default.
• W2557703775 hasPrimaryLocation W25577037751 @default.
• W2557703775 hasRelatedWork W185296467 @default.
• W2557703775 hasRelatedWork W1945359667 @default.
• W2557703775 hasRelatedWork W1973460911 @default.
• W2557703775 hasRelatedWork W2096903645 @default.
• W2557703775 hasRelatedWork W2140033339 @default.
• W2557703775 hasRelatedWork W2417908219 @default.
• W2557703775 hasRelatedWork W2465215300 @default.
• W2557703775 hasRelatedWork W4255640712 @default.
• W2557703775 hasRelatedWork W4300011733 @default.
• W2557703775 hasRelatedWork W1543146126 @default.
• W2557703775 hasVolume "74" @default.
• W2557703775 isParatext "false" @default.
• W2557703775 isRetracted "false" @default.
• W2557703775 magId "2557703775" @default.

• next